Dr Reddys Laboratories (RDY) Cash from Financing Activities (2009)
Dr Reddys Laboratories (RDY) posted quarterly Cash from Financing Activities of -$38.0 million for Q4 2009, up 34.48% quarter-over-quarter from -$58.0 million in Q3 2009.
Dr Reddys Laboratories (RDY) Cash from Financing Activities (2009) Analysis & Trends
Dr Reddys Laboratories' Cash from Financing Activities history runs 1 years deep, the most recent figure standing at -$38.0 million for Q4 2009.
- In Q4 2009, Cash from Financing Activities changed N/A year-over-year to -$38.0 million; the TTM figure through Dec 2009 stood at -$182.3 million (changed N/A YoY), while the FY2026 annual figure was $88.0 million, down 60.36% from the prior year.
- Cash from Financing Activities for Q4 2009 stood at -$38.0 million, up from -$58.0 million in the prior quarter.
- The five-year high for Cash from Financing Activities was -$38.0 million in Q4 2009, with the low at -$83.0 million in Q2 2009.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.41 Bn | 39.75 Bn | 2.15 Bn | -1.00 Mn |
| 3 | Zoetis | 31.83 Bn | 30.15 Bn | 1.05 Bn | -813.00 Mn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.97 Bn | 5.10 Bn | -1.13 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 122.40 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | -1.24 Bn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 63.40 Mn |
| 8 | Elanco Animal Health | 11.93 Bn | 11.40 Bn | 798.00 Mn | -74.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | - |
| 10 | Alkermes | 8.20 Bn | 7.55 Bn | 397.90 Mn | 17.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2009 | -38.00 Mn |
| Dec 31, 2009 | -38.00 Mn |
| Sep 30, 2009 | -58.00 Mn |
| Sep 30, 2009 | -58.00 Mn |
| Jun 30, 2009 | -83.00 Mn |
| Jun 30, 2009 | -83.00 Mn |